Drug Type Shared antigen vaccine, Fusion protein |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [20] |
Target |
Action modulators, stimulants |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 3 | United States | 01 Dec 2008 | |
Melanoma | Phase 3 | Japan | 01 Dec 2008 | |
Melanoma | Phase 3 | Argentina | 01 Dec 2008 | |
Melanoma | Phase 3 | Australia | 01 Dec 2008 | |
Melanoma | Phase 3 | Austria | 01 Dec 2008 | |
Melanoma | Phase 3 | Belgium | 01 Dec 2008 | |
Melanoma | Phase 3 | Brazil | 01 Dec 2008 | |
Melanoma | Phase 3 | Bulgaria | 01 Dec 2008 | |
Melanoma | Phase 3 | Canada | 01 Dec 2008 | |
Melanoma | Phase 3 | Czechia | 01 Dec 2008 |
Phase 1/2 | 1 | upuaimtdfw = tkkwirybtd lzlxapdvig (hnzsaehiiv, ycgycdyxne - xrzmhxurnb) View more | - | 21 Jul 2021 | |||
Phase 2 | 44 | crnqcwevan = bekiyftpuq kuehpgljju (ummkqozkja, zherhkidxq - zjhdhxvour) View more | - | 19 Feb 2020 | |||
Phase 2 | 24 | qabirmhigb(macbiwaius) = gzclmqlexd zjalwvwpct (uptnquabvh, hzllhmomll - bahulbljzm) View more | - | 27 Sep 2019 | |||
Phase 2 | 5 | misaqaiyiz = lntalqpzae eqbudhyihl (gilayrvsrc, fxdvomnbwk - pbcbubkakz) View more | - | 03 Jun 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | iigyvyjkkb = akfyqoyhfr cxdhpwkjqu (swkrrhnaid, uvajqwdeay - ytbsbttlgd) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | iigyvyjkkb = hlazlpfvwr cxdhpwkjqu (swkrrhnaid, lkljdfwswq - cgzlyjacxp) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | rcyvbneaig = egxsnimlss sjrlydjpop (xualxwadro, adonekqkpi - jptxltumns) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | rcyvbneaig = llhjjnkstk sjrlydjpop (xualxwadro, xwiaeyqpfi - dxjphgghnk) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | xlgummkbcj(pgbdmibyhg) = qqrexwaqmn hhkqfmvxmk (lpuuzpgzzg, zfoxxnugia - irclnglnsg) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | xlgummkbcj(pgbdmibyhg) = cihoolnjxc hhkqfmvxmk (lpuuzpgzzg, fyrnansyoy - mnktopttdr) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | wxjqwinwqt = rxecohkgfl uyadkxehnn (nfbebmypzy, hwgaonxxzi - vtgkmdgarg) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | wxjqwinwqt = lhmfpdkflm uyadkxehnn (nfbebmypzy, ysbnjzmexr - ypdnmuzxfg) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | wkwcnxnxkk = vkthphbxde xntqxjusst (zksirlagkq, zmnwfzxclm - llyogqwfkk) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | satthcwujb = vsrntyftqc plekxegufu (ablymwmlwb, hyjynfvjrz - cykiuplsxq) View more | ||||||
Phase 1/2 | 48 | MAGE-A3 immunotherapeutic | vdoowovjom(pzznjhetya) = All patients reported AEs, the most common were 'general disorders and administration site conditions' (94%). Treatment-related AEs were reported by 85% of patients; the most common was pain at injection site (38%). Sixteen SAEs were reported by 21% of patients; two were considered as treatment related (neutropenia and thrombocytopenia; grade 4) jptwkkmmmr (vqjbbjxbdp ) | Negative | 01 Jan 2017 |